Fig. 1

Manufacture of TX200-TR101 for use in kidney transplantation. (1) HLA-A*02-negative kidney transplant recipients designated to receive a mismatched HLA-A*02–positive organ undergo leukapheresis to collect white blood cells. (2) Naive Tregs (CD4⁺/CD45RA⁺/CD25⁺/CD127^low/neg) are isolated, transduced with a lentiviral vector encoding the HLA-A2-CAR and expanded ex vivo before cryopreservation of the drug product (TX200-TR101). (3) The transplant recipient will receive an intravenous infusion of the autologous HLA-A2-CAR-Tregs between 2 and 3 months after kidney transplantation. CAR, chimeric antigen receptor; CD, cluster of differentiation; CMO, contract manufacturing organisation; HLA-A*02, human leukocyte antigen class I molecule A*02; Tregs, regulatory T cells